SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development
The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.
SGS has entered into a collaboration with DiscoverX, an innovative life science company that supplies cell-based assays and services for drug discovery and development. Under the terms of the agreement, SGS and DiscoverX will work together to provide simple and qualified assays for functional comparability, for use in quality control (QC), lot release, and stability testing of biosimilars and biobetters, offering products as well as services.
DiscoverX has developed ready-to-use bioassays for a number of biologic drugs that are set to lose patent protection over the next 10 years. SGS has initiated the evaluation and qualification of these assays and plans to offer these as a service within a Good Manufacturing Practice (GMP) or Good Clinical Practice (GCP) environment for clients. The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures, and enable them to rapidly advance to qualification and assay validation for potency and neutralizing-antibody assays.
“These assays are simple to use and generate accurate, robust and reproducible results, which can accelerate the process of demonstrating biosimilarity, and the development of lot release assays for drug candidates,” commented Fiona Greer, Global Director, Biopharma Services Development at SGS. “By combining SGS’s vast knowledge in bioanalysis, with the experience DiscoverX has in developing innovative cell-based assays, this collaboration will bring value to clients of both companies.”
“DiscoverX has developed industry-leading cell-based assays for bio-comparability and lot release testing of biosimilar drugs. These assays are available to our clients to use as a product and now, partnering with SGS allows us to offer these assays as GMP and GCP services as well,” said Dr. Todd Nelson, CEO of DiscoverX. Dr Nelson continued: “This partnership will provide simple, qualified, fit-for-purpose bioassays for QC lot release and stability testing of biosimilars and biobetters to clients globally.”
Data on the first assay qualification studies will be presented at the CASSS Bioassays 2016 Conference in Silver Spring, MD. SGS will offer the functional comparability assay services to clients under GMP/GCP from its Poitiers, France laboratory. This new service will be supported by SGS’s existing characterization and analytical capabilities across its global network.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance